RxDoctor Payments Data

Sudhir Khanna, MD

Internal Medicine · Shamokin, PANPI 1801892583

Payments from drug & device makers

$6,978in general payments, 2019–2025

Across 444 payments — averaging $15.72 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$809
  • Lilly USA, LLC$713
  • AstraZeneca$688
  • Bayer$542
  • Esperion Therapeutics, Inc.$535
  • Johnson & Johnson$533
  • plus $3K from 20 others

What the payments were for

  • Food & beverage$6,88099%
  • Education$991%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$6,978 in reported general payments places this provider in the 90th percentile of 5,705 internal medicine providers in Pennsylvania.

See all internal medicine providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$82,992
Medicare patients
104
Services billed
1,230

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide244$236,435
EliquisApixaban66$70,281
OtezlaApremilast11$55,906
XareltoRivaroxaban35$50,743
JardianceEmpagliflozin39$42,876
Trelegy ElliptaFluticasone/Umeclidin/Vilanter22$22,698
TradjentaLinagliptin30$18,952
TrulicityDulaglutide12$14,669
Atorvastatin Calcium482$7,045
NexlizetBempedoic Acid/Ezetimibe11$6,390
Varenicline Tartrate14$5,964
Novolog Mix 70-30 FlexpenInsulin Aspart Prot/Insuln Asp11$5,311
Metoprolol Succinate189$4,893
Irbesartan138$4,646
Ezetimibe160$4,318

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$809$236,435244 claims
PfizerEliquis$181$70,28166 claims
Boehringer IngelheimJardiance, Tradjenta$531$61,82869 claims
AmgenOtezla$438$55,90611 claims
Johnson & JohnsonXarelto$533$50,74335 claims
GSKTrelegy Ellipta$115$22,69822 claims
Lilly USA, LLCTrulicity$713$14,66912 claims
Esperion Therapeutics, Inc.Nexlizet$535$6,39011 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 5,705 internal medicine providers in Pennsylvania.

Other internal medicine in Shamokin

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →